RENALYTIX PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.5 GBX | -3.92% |
|
-18.33% | +58.06% |
| Apr. 18 | Renalytix chief business officer to become president | AN |
| Apr. 18 | Renalytix Names Chief Business Officer as President | MT |
Valuation
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 205 | 390.1 | 1,078 | 95.45 | 133.9 | 47.11 | - | - |
| Enterprise Value (EV) 1 | 195.7 | 377.3 | 1,013 | 66.46 | 121.2 | 47.11 | 47.11 | 47.11 |
| P/E ratio | - | -41 x | -34.7 x | -1.64 x | -2.55 x | - | - | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 723 x | 32.1 x | 39.4 x | 11.8 x | 2.62 x | 0.79 x |
| EV / Revenue | - | - | 723 x | 32.1 x | 39.4 x | 11.8 x | 2.62 x | 0.79 x |
| EV / EBITDA | -37,874,147 x | -39,667,398 x | -35,317,377 x | -1,811,193 x | -3,200,093 x | - | - | - |
| EV / FCF | - | -37,508,576 x | -36,957,821 x | -2,053,446 x | -4,098,498 x | - | - | - |
| FCF Yield | - | -0% | -0% | -0% | -0% | - | - | - |
| Price to Book | 7.28 x | 9.83 x | 11.5 x | 2.21 x | - | - | - | - |
| Nbr of stocks (in thousands) | 53,816 | 59,416 | 72,197 | 74,760 | 93,781 | 154,368 | - | - |
| Reference price 2 | 3.809 | 6.565 | 14.93 | 1.277 | 1.428 | 0.3052 | 0.3052 | 0.3052 |
| Announcement Date | 9/3/19 | 10/27/20 | 10/21/21 | 10/31/22 | 9/28/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 1.491 | 2.97 | 3.403 | 4 | 18 | 60 |
| EBITDA | -5.412 | -9.834 | -30.53 | -52.7 | -41.85 | - | - | - |
| EBIT 1 | -6.537 | -11.08 | -32.61 | -57.37 | -42.36 | -32.2 | -26.6 | 0.7 |
| Operating Margin | - | - | -2,187.19% | -1,931.72% | -1,244.64% | -805% | -147.78% | 1.17% |
| Earnings before Tax (EBT) | - | -10.61 | -35.79 | -49.63 | -46.22 | - | - | - |
| Net income 1 | - | -9.25 | -31.01 | -56.65 | -46.22 | -35.5 | -26.7 | 0.6 |
| Net margin | - | - | -2,079.75% | -1,907.34% | -1,358.3% | -887.5% | -148.33% | 1% |
| EPS | - | -0.1600 | -0.4300 | -0.7800 | -0.5600 | - | - | - |
| Free Cash Flow | - | -10.4 | -29.17 | -46.48 | -32.67 | - | - | - |
| FCF margin | - | - | -1,956.54% | -1,565.02% | -960.15% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 9/3/19 | 10/27/20 | 10/21/21 | 10/31/22 | 9/28/23 | - | - | - |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2020 S1 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.482 | 0.845 | 0.812 | 0.831 | 0.969 | 1.192 | 0.724 | 0.518 | 0.459 | 0.709 | 1.1 | 1.6 | 2.5 | 3.8 | 4.7 |
| EBITDA | - | -11.76 | -13.74 | -14.44 | -15.8 | -11.6 | -9.527 | -10.79 | -9.948 | -8.762 | -8.227 | - | - | - | - | - |
| EBIT 1 | - | -11.88 | -13.85 | -14.57 | -17.24 | -11.73 | -9.655 | -10.92 | -10.07 | -8.889 | -8.335 | -8.4 | -8.2 | -7.7 | -7.1 | -6.5 |
| Operating Margin | - | -2,463.69% | -1,639.29% | -1,794.21% | -2,074.49% | -1,210.94% | -809.98% | -1,507.87% | -1,943.63% | -1,936.6% | -1,175.6% | -763.64% | -512.5% | -308% | -186.84% | -138.3% |
| Earnings before Tax (EBT) | - | -10.11 | -15.32 | -14.7 | -9.505 | - | -10.44 | -12.11 | -11.72 | -10.15 | - | - | - | - | - | - |
| Net income 1 | -3.767 | -10.11 | -15.32 | -14.7 | -16.52 | -11.95 | -10.44 | -12.11 | -11.72 | -10.15 | -8.485 | -8.5 | -8.2 | -7.7 | -7.1 | -6.5 |
| Net margin | - | -2,096.68% | -1,813.25% | -1,809.73% | -1,988.57% | -1,233.54% | -876.17% | -1,672.1% | -2,262.16% | -2,212.2% | -1,196.76% | -772.73% | -512.5% | -308% | -186.84% | -138.3% |
| EPS | -0.000600 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/3/20 | 12/7/21 | 3/31/22 | 6/30/22 | 10/31/22 | 11/30/22 | 3/30/23 | 6/9/23 | 9/28/23 | 11/14/23 | 2/14/24 | - | - | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 9.29 | 12.8 | 64.8 | 29 | 12.7 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | -10.4 | -29.2 | -46.5 | -32.7 | - | - | - |
| ROE (net income / shareholders' equity) | - | -28.8% | -48% | -131% | -150% | - | - | - |
| ROA (Net income/ Total Assets) | - | -26.3% | -43.8% | - | - | - | - | - |
| Assets 1 | - | 35.11 | 70.83 | - | - | - | - | - |
| Book Value Per Share | 0.5200 | 0.6700 | 1.300 | 0.5800 | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | 0.34 | 0.77 | - | - | - | - | - |
| Capex / Sales | - | - | 51.84% | - | - | - | - | - |
| Announcement Date | 9/3/19 | 10/27/20 | 10/21/21 | 10/31/22 | 9/28/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.245
Average target price
-
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +58.06% | 47.11M | |
| -12.91% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| +23.78% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -7.14% | 716M | |
| -18.10% | 682M |
- Stock Market
- Equities
- RENX Stock
- Financials Renalytix Plc
